mediarelease

Alvogen, Inc. (Alvogen), the U.S.-based pharmaceutical company,
today announced that it has expanded operations in Eastern Europe and
has opened an office in Bucharest, Romania. Alvogen Romania
primarily will focus on sales and marketing to support several new
products scheduled for introduction during 2010. The company also will
employ regulatory and pharmacovigilance expertise within the newly
formed business.

“We see great opportunities for our business in Eastern Europe, and the
creation of Alvogen Romania is integral to our development strategy.
Through registration of our own products, portfolio acquisitions and
strategic partnerships, we aim to build a strong presence in the market
with a targeted product offering,” said Robert Wessman, Executive
Chairman of Alvogen. Wessman is the former chief executive of
Actavis, one of the largest generic pharmaceutical companies in the
world.

Alvogen Romania will be led by Laurentiu Scheusan, a recognized
expert in the Romanian pharmaceutical market who formerly managed local
operations for generic pharmaceuticals company Actavis. In his role as
Managing Director of Alvogen Romania, Scheusan will lead more than
60 new employees who have measurable experience within the local
pharmaceutical industry.

The well-established, Romanian pharmaceutical market generates annual
sales totaling $3 billion (USD), and Alvogen believes the market will
experience strong growth as the Romanian healthcare infrastructure
improves.

“Within the next five years we aim to be one of the leading
pharmaceutical companies in Romania, based upon our reputation of high
quality products and services,” said Doug Drysdale, Chief Executive
Officer of Alvogen. “It is our vision to set a new standard for the
generic pharmaceutical business, enhance the quality of life for
patients and deliver exceptional value to our customers,” said Drysdale.

About Alvogen

Alvogen is a multinational pharmaceuticals company focused on
complex generic products. Alvogen is committed to build the
next-generation generics company through the strategic selection of
products, partners and markets, and the utilization of a consolidated
global supply chain. The company has more than 130 pharmaceutical
products in development and registration with several products expected
to be launched in 2010. The product portfolio consists of a broad range
of leading molecules for the treatment of conditions in the areas of
Oncology, Cardiology, Respiratory, Neurology and Gastroenterology.

With more than 100 years in operation, Alvogen possesses first-class
regulatory, development and manufacturing capabilities in Asia, Europe
and North America. Visit www.alvogen.com
for additional information.

save this article as .pdf.